A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study
β Scribed by Timothy M. Kuzel; Martin S. Tallman; Daniel Shevrin; Edward Braud; Lary Kilton; Patricia Johnson; James Kozlowski; Nicholas J. Vogelzang; Richard Blough; Al B. Benson III
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 388 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas
In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c
Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer
n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our